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Next Generation Sequencing Claims in Precision Medicine: Questions a Formulary Committee Should Ask 
Paul C Langley PhD, Adjunct Professor, University of Minnesota 
 
Abstract 
The enthusiasm with which precision medicine has been embraced over the past 15 years has obscured the fact that the evidence 
base for biomarker-driven assessments, in particular for next generation sequencing (NGS), is limited. This applies both to the 
comparative performance of the various assessment tools as well as to the impact of biomarker driven decisions at the patient level. 
Where a genetic test is being evaluated there are five key questions a formulary committee should ask when assessing whether or 
not to recommend coverage and reimbursement for the test in target patient populations:  
 
(i) has the test met required standards for analytic and clinical validity?  
(ii) has the test been evaluated against competing tests for analytic and clinical validity?  
(iii) have the test-based claims met standards for credibility, evaluation and replication? 
(iv) has the test been accepted as part of the standard of care for patient management in the target disease state?  
(v) has the introduction of the test improved outcomes, including survivorship, adverse events, quality of life and costs, in 
the targeted population? 
The purpose of this commentary is twofold: first, to consider the appropriate evidentiary standards for the evaluation of a test and 
comparator tests; and, second, to identify questions that a formulary committee should address in submissions made for a test in 
health care systems. A critical issue is not only comparative claims for the test against the standard of care and comparator tests, but 
the assessment of test performance for the identified treatment pathways where mutations or variants are linked to 
recommendations for therapy options. Unless these issues are addressed it is unlikely that the promise of personalized medicine will 
be realized. The absence of an evidence base will deter both physicians and their patients from adopting NGS based 
recommendations.  
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INTRODUCTION 
A major, if not the principal objection, to precision medicine 
interventions is the lack of a robust and comprehensive 
evidence base to support claims that the new paradigm will 
materially improve patient outcomes and, hopefully, reduce 
costs 1 2. Faced with a dearth of evidence that claims for 
precision medicine interventions are credible, evaluable and 
replicable, health systems are understandably reluctant to 
embrace this paradigm.  
 
In many respects, the lack of evidence to support claims in 
precision medicine and the reluctance to underwrite tests 
both for older style genomic targeting and the current flavor 
of the month, next generation sequencing (NGS), is little 
different from the lack of evidence for claims in traditional 
pharmaceutical products. More specifically: the lack of claims 
that are credible, the lack of claims that are evaluable and the 
lack of claims that can be replicated 3 4. Formulary  
committees and other health care decision makers are asked 
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to take on board such claims. These include modeled 
extrapolations from short-term phase 3 trials as well as  
the absurd lifetime cost-per-QALY models favored by groups 
in the US such as the Academy of Managed Care Pharmacy 
(AMCP) and the Institute for Clinical Effectiveness Research 
(ICER) and their progenitor the National Institute for Care and 
Health Excellence (NICE) reference case in the UK 5 6 7. At the 
same time, journal editors seem wedded to support the 
proliferation of lifetime cost-per-QALY models 8 9 10. 
Understandably, there is little evidence to suggest that these 
models actually influence formulary decisions in the US. 
 
Central to the demand for claims that are credible, evaluable 
and replicable is the issue of clinical utility: the ability of a 
screening or diagnostic test to support diagnosis, treatment 
interventions, outcomes, disease management and  prevent 
or ameliorate adverse health outcomes’11 12. In precision 
medicine the test platform is the treatment gatekeeper:  the 
choice of intervention relies upon the accuracy of the test 
while c claims for clinical utility rest upon test performance. 
The National Institutes of Health – Department of Energy 
Task Force on Genetic Testing reporting in 1997 defined the 
clinical utility of a test as ‘the balance of benefits to risks’ 13. 
While there is obviously a debate as to how broadly the 
benefits of testing are to be defined, there is agreement that 
Commentary FORMULARY EVALUATIONS 
 
http://z.umn.edu/INNOVATIONS                         2016, Vol. 7, No. 4, Article 11                          INNOVATIONS in pharmacy   2 
 
the primary benefit is the ability of the test to inform clinical 
practice.  
 
From a public health perspective, the evidence to support 
health impacts is a critical input to setting public priorities 
and evaluating clinical utility, with the caveat that these must 
be evidence based. There is no inherent utility in a test unless 
patients in targeted groups have access to that test and 
claims based on that test can be evaluated. The acceptance 
or otherwise of a test should not rest solely on claims for 
analytical or clinical validity. Rather the test outcomes should 
be evaluated against standards that apply to claims for 
pharmaceuticals: are the claims made for the test in clinical 
practice credible, evaluable and replicable? In other words, 
does evidence for the test (or more broadly, the test) meet 
the standards of normal science 14 15.  
 
If the standards of normal science are applied then we might 
usefully point to a list of core questions that a formulary 
committee, health care decision or professional clinical group 
might ask before approving a particular test for 
reimbursement or inclusion in a treatment guideline. These 
are: 
(i) has the test met required standards for analytic 
and clinical validity?  
(ii) has the test been evaluated against competing 
tests for analytic and clinical validity?  
(iii) have the test claims for outcomes and costs in 
target treating populations met standards for 
credibility, evaluation and replication? 
(iv) has the test been accepted as part of the 
standard of care for patient management in the 
target disease state?  
(v) has the introduction of the test improved 
outcomes, including survivorship, adverse 
events, quality of life and costs, in the targeted 
population compared to the standard of care 
There is no reason why a formulary committee of other 
health decision maker should assume that making a NGS test 
available, even if restricted to target population groups 
within disease states, will necessarily improve outcomes. 
After all, there are questions of the uptake of tests ordered 
by physicians, how a physician implements the test therapy 
recommendations, adherence and persistent with therapy 
choices (which may involve complex polytherapy) and the 
timeframe over which the outcomes for treated patients are 
monitored.  
 
Once rates of uptake and implementation, together with 
adherence and persistence with therapy are factored into the 
assessment, the result from a well- designed, protocol driven 
observational study may conclude that the outcomes for the 
target group are inferior to those with the standard of care. 
Claims that the outcomes will inevitably be better because 
they address the issue of tumor heterogeneity may simply 
evaporate in clinical practice. 
 
The onus is on the test developer or vendor to ensure that 
there is feedback to health systems, treating physicians and 
patients that it is worth investing in an NGS test; and, possibly 
more to the point, that investing in their test is more cost-
effective than an investment in any one of a number of 
competing NGS tests. There are two reasons for this: (i) tests 
may differ in their platform, process and structure and (ii) 
there is no necessary expectation that different tests will 
generate similar recommendations for matching 
pharmaceutical compounds to genetic markers or that the 
same genetic markers will be identified. Claims for test 
performance and outcomes from their application must, 
therefore, be comparative.  
 
Care must be taken, however, in establishing the basis for 
NGS test comparison (or a comparison against the standard 
of care). Irrespective of whether or not the assessment is 
through a randomized clinical trial (RCT)(e.g., an umbrella 
trial – see below) or through a prospective, protocol driven 
observational study, the focus is on the response by patients 
to the recommended therapies driven by the NGS platform. 
Matching therapies to mutations may result in a 
recommendation for a monotherapy matched to a single 
mutation (or cluster of mutations) or more complex 
polytherapy choices matched to a different cluster of 
mutations.  
 
Assessments, therefore, should be in terms of the various 
therapy choices not just on the expressed mutations. One 
approach, given the inherent heterogeneity of mutations 
within tumor types is to focus the assessment on the most 
frequently reported mutation clusters, defined at the level of 
the individual patient enrolled in the study. The study may, 
for example, recruit patients in the top 5 or 10 most 
frequently reported mutation clusters with their associated 
therapies. These clusters would define the treatment arms 
within an RCT design or the selection of patients to be 
tracked in an observational study. The advantage of the 
observational study is that the starting point could be 
physicians who request a test, following through on those 
physicians who implement (or attempt to implement) the 
recommendations. Needless to say, both RCTs and 
observational assessments would have to be disease specific, 
focusing on target populations within the care pathway. After 
all, claims for one NGS test platform in one target population 
is no guarantee that a similar response would be expected in 
in another disease state.   
 
Where a modeled claim accompanies a formulary submission 
for a NGS test, the model should attempt to capture 
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treatment pathways defined in terms of the standard(s) of 
care and the most frequently reported mutation and hence 
therapy clusters. Unfortunately, with the limited data yet 
available on therapy cluster outcomes from either RCTs or 
observational studies this is difficult to accomplish. We have 
yet to see the expected wave of extrapolated lifetime cost-
per-QALY (quality adjusted life year) precision medicine 
decision models to support claims from competing NGS 
platforms. Models that claim that an ‘acceptable’ accuracy 
response threshold from a NGS test demonstrates that the 
sponsor’s test will, with appropriate corrections for structural 
and parameter uncertainty, together with a judicial choice of 
Markov framework, lead to increased survival, less toxicity, 
improved quality of life and lower costs in a target 
population.  
 
Presenting non-evaluable modeled claims that the up-front 
cost of the genomic test and potentially subsequent tests to 
check the course of the disease and patient response should 
be seen as sufficient justification for investing in an NGS test 
are unacceptable. Attempting to justify the cost-effectiveness 
of an NGS test through modeling, even if the model generates 
cost-per-QALY estimates appropriately falling below the 
magic $50,000 threshold is also not acceptable. Just as in the 
case of drug products, the claims made will either lack 
credibility (e.g., cost-per-QALY saved over the lifetime of the 
patient cohort), will be difficult if not impossible to evaluate 
with existing data (QALY claims again) and, by extension, be 
impossible to replicate. In order to forestall such an 
eventuality, it is important that health care decision makers 
to set standards for claims credibility, evaluation and 
replications for NGS tests. The losers in these scenarios will 
be health systems. They will be asked to support 
reimbursement for the test while treating physicians will be 
reluctant to order or implement test claims given the limited 
evidence for outcomes and costs. The fact that treatment 
guidelines may recommend genomic assessments at 
particular disease stages is no guarantee that they will be 
followed through or their recommendations for drug 
repositioning acted on. Tests may be ordered and the results 
put to one side. 
 
The absence of credible, evaluable and replicable claims for 
drug products in formulary submissions was the genesis 
behind the recently published proposed guidelines for 
formulary evaluation developed by the Program in Social and 
Administrative Pharmacy at the University of Minnesota 16. 
The proposed guidelines, while not rejecting modeled claims 
for clinical comparisons and cost-effectiveness, ask that the 
claims submitted meet the standards of normal science. To 
support this, manufacturers making a submission were asked 
to submit a protocol detailing how the claims were to be 
assessed and reported back to the formulary committee in a 
meaningful timeframe. At the same time, even if the 
manufacturer could claim that it had undertaken such an 
exercise with another health system and could produce the 
results as, hopefully, a peer reviewed publication, the option 
was still open for the health system to request the 
manufacturer to support a further claims assessment study. 
 
Replication of test claims is, in many ways, the critical issue. 
Apart from the obvious point that the process of conjecture 
and refutation underpins our notion of scientific progress 
(and has done for last least last 350 years – or earlier if we 
accept the contributions of Francis Bacon 17), there is a long 
standing concern with the absence of studies that are 
directed to replicating claims from clinical trials and, where 
such efforts have been undertaken, the limited evidence for 
claims replication. In the case of tests, formulary committee 
should be insistent that, in approving and reimbursing a test, 
evidence is presented that the molecular targets identified, 
their distribution and claims for clinical impact can be 
replicated in target populations.  
 
COMMENTARY OUTLINE 
The first part of this commentary addresses the issue of 
current evidentiary standards for evaluating NGS platforms 
and, more generally, diagnostic tests. Standards proposed by 
NICE under the Diagnostic Assessment Programme (DAP) are 
reviewed. These standards are of interest, not only because 
they point to the importance of identifying the place of a test 
in therapy for a target population but they link claims for test 
accuracy to establishing a modeled cost-per-QALY case for 
the test. At the same time, it is important to address the 
critical importance (which NICE emphasizes) of ensuring that 
evidence presented is robust and meets accepted standards 
in master protocol trial design, and that the test have been 
approved by responsible agencies. 
 
As a major theme in this commentary is on the need to 
evaluate tests that are specific to target populations, the 
commentary then addresses the importance of identifying 
the characteristics of the target population and the expected 
place of a test in the treatment pathway. It is argued that it is 
unwise to expect blanket approval for an NGS test across 
target populations in disease areas. Rather, health care 
decision makers should insist on robust evidence from both 
clinical trials and observational studies to demonstrate that 
the test has claims relevant to that group and the stage of 
disease. 
 
The first step in developing a robust case for any test is to 
ensure that the test meets standards for analytical and 
clinical validity. These issues are reviewed from the 
perspective of both the Center for Medicare and Medicaid 
Services (CMS) and the Food and Drug Administration (FDA). 
The issue is whether or not platform NGS tests should be 
seen as medical devices. If they are (as seems likely) the 
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question is what standards and possible monitoring will the 
FDA require to approve these tests?  
 
In addition to possible standards for individual NGS test 
approval, further issues that are addressed are (i) whether or 
not NGS test platforms should be compared in terms of both 
their accuracy and the prognostic claims made for linking 
mutations to drug products and (ii) the standards that would 
be expected not only for integrating NGS test 
recommendations in treatment guidelines. It would be 
possibly unwise, given issues of efficacy and safety, for 
treatment guidelines to indicate that any NGS test may be 
appropriate at a particular point in a treatment pathway. 
Professional groups may wish to nominate specific NGS 
platforms with a recognized evidence-based contribution to 
therapy choices alongside the standard of care. Professional 
groups should indicate why a particular platform is 
recommended along with details on the platform structure 
and standard operating procedures in place for curating and 
updating the platform. 
 
The commentary details recommended evidentiary standards 
for both clinical trials and observational studies that support 
claims for test performance in target populations. These 
would support modeled claims for the test. Where modeled 
claims and claims from trials and observational studies are 
presented these should apply (i) to the overall test 
performance and (ii) the proposed treatment pathways 
defined by the recommended monotherapy and polytherapy 
therapy choices linked to observed mutation clusters.  
 
The commentary concludes by detailing (i) a proposed 
submission format for an NGS test and (ii) a list of 40 
questions that a formulary committee should consider in 
evaluating the submission. As emphasized above, the claims 
made should be credible, evaluable and replicable. The 
submission should be accompanied by a protocol to describe 
how the prognostic claims from the test might be evaluated. 
The protocol should take into account mutation 
heterogeneity within, for example, tumors and whether the 
test should be re-administered given tumor progression. The 
protocol should describe how it is proposed to provide 
feedback to the health system as well as feedback on 
enhancements or modifications to the NGS platform.  
 
THE NICE DIAGNOSTIC ASSESSMENT PROGRAMME 
A useful reference point in considering the evidence 
standards for formulary submissions to support approval and 
reimbursement of a test is the DAP introduced by NICE in the 
UK in 201118. Although the program process and conclusions 
regarding clinical and cost-effectiveness are focused on the 
assessment and implementation of the test within the 
National Health Service (NHS) the DAP is relevant for 
manufacturers in the US. Manufacturers may on the one 
hand be considering the UK as a potential market will have to 
meet DAP standards while on the other hand there may be 
groups in the US (e.g., the ICER) who may take the 
opportunity to apply their NICE-derived willingness-to-pay 
methodology to make recommendations for the cost-
effectiveness of competing tests. 
 
Key features of the NICE DAP are: 
• Developing the scope of the assessment 
o Identify the target patient population, 
capturing the aetiology of the disease, 
disease stage, grade or severity, factors that 
may impact the accuracy of the test, as well 
as these benefits or risks of treatment such 
as comorbidities and age, gender and 
ethnicity 
o Describe of the test, its place in therapy and 
the setting for the test 
o Detail expected outcomes, costs and time 
horizon for the analysis within the care 
pathway 
• Evidence assessment and evaluation 
o Identify and synthesize the evidence for 
diagnostic test accuracy utilizing systematic 
reviews, assessments of variability in results 
and potential biases, meta-analyses for 
sensitivity and specificity, likelihood ratios 
and predictive values, odds ratios, summary 
receiver operating characteristic (ROC) 
analyses and hierarchical models  
o Identify and synthesize evidence for health 
outcomes to include evidence for cost-
effectiveness focusing on costs and 
resource use, duration and quality of life 
• Modeling clinical outcomes and cost-effectiveness 
o Simplified analyses: where a test is superior 
to comparators in its analytical validity and 
no worse in direct side effects, possibly 
qualified by test cost, more complex 
assessment may be unnecessary 
o Assessment structure: if final data on test 
outcomes in target population limited it 
may be necessary to combine evidence 
from care pathway to link diagnosis, 
treatment and final outcomes 
o Test accuracy: summarize analytical validity 
assessments 
o Diagnostic process: test and potential test 
sequences 
o Reference case: application of modeled 
cost-utility analysis over relevant time 
horizon  
o Outcomes: QALYs 
o Evidence on resource use and costs 
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o Discounting costs and benefits 
o Characterize bias and uncertainty in model 
structure and data inputs 
o Application and selection of patient sub-
groups 
When a submission is requested by NICE, it is typically 
referred to an external assessment group who develop a 
diagnostics assessment report for review by stakeholders 
(defined in the assessment scope). A final review and report 
is prepared by NICE and a diagnostic guidance drafted. The 
draft guidance is reviewed, issues resolved and then 
published by NICE for the NHS. 
 
While the NICE process is a useful benchmark, it is unlikely 
that a health system in the US (other than a government 
agency) would have the resources to undertake such an 
extensive review. Also, given the lack of interest in QALY 
measures, it is unlikely that a reference case modeling would 
resonate with health system decision makers. The questions 
proposed here are considered more in line with what is 
feasible in the US environment. 
 
EVIDENTIARY STANDARDS FOR A TEST SUBMISSION 
The evidence to support claims for analytical validity, clinical 
validity and outcomes must conform to accepted standards. If 
these standards are not met, the test submission should be 
returned to the manufacturer. Recommended standards 
would include reporting: 
(a) Diagnostic Accuracy and Quality  
 
Diagnostic Accuracy: All studies referenced to 
support claims for diagnostic accuracy for the target 
test and comparators should be evaluated against 
the STARD 2015 (Standards for Reporting of 
Diagnostic Accuracy Studies) statement 19. Each 
study reported should be scored. 
  
Quality Assessment and Bias: all studies referenced 
to support claims for diagnostic accuracy should also 
be appraised for quality and bias against the 
QUADAS-2 tool (Quality Assessment of Diagnostic 
Accuracy Studies) 20. Each study reported should be 
scored. 
 
(b) Systematic Reviews 
Whenever a systematic review is requested to 
support the test and comparator evidence base it 
must conform to the PISMA-P 2015 standards21. 
Apart from the usual databases (e.g. PubMed), 
reference should also be made for reviews focused 
on the CDC Public Health Genomics Knowledge Base 
22.  
(c) Reporting Randomized Trials 
Reporting of results from randomized clinical trials of 
test performance should conform to the 
Consolidated Standards of Reporting Trials 
(CONSORT) 23 . This is a standard format for 
reporting on trial organization, analysis and 
interpretation. The CONSORT Statement comprises a 
25-item check list and flow diagram to record the 
progress of patients through the trial.  
(d) Evidence Hierarchy  
Claims for the efficacy or effectiveness of tests in 
clinical practice must be founded on high quality and 
bias-free evidence. Where a submission has 
undertaken a systematic review or relies upon 
individual studies to support credible, evaluable and 
replicable claims the evidence presented should be 
assessed against the standards established within 
the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) working 
groups. The GRADE framework has superseded 
earlier proposals for the ranking of evidence (which 
typically ranks from randomized trials through to 
observational studies and anecdotal, key opinion 
leader evidence) to a more flexible evidence 
hierarchy addressing the quality of evidence for 
individual outcomes.  Specifically: bias, 
inconsistency, indirectness, imprecision and 
publication bias 24.  
The GRADE framework is intended to apply to meta-
analyses from systematic reviews but can be applied 
to individual studies or non-quantitative syntheses. 
The essence of the GRADE approach is that, within 
each hierarchy level, it allows the downgrading or 
upgrading of evidence. Downgrading, for example in 
the case of randomized clinical trials, occurs if there 
is a risk of bias, inconsistency, indirectness, 
imprecision and publication bias. Upgrading, for 
example in the case of non-randomized studies can 
occur if there is a large magnitude of effect, 
evidence of a dose response effect and if all 
plausible confounding factors have been taken into 
account. The application of the GRADE framework a 
4-level quality rating hierarchy. This is detailed in the 
Cochrane Collaboration handbook 25.  
1. High Quality Rating: Randomized trials; or 
double-upgraded observational studies 
2. Moderate Quality Rating: Randomized 
trials; or upgraded observational studies 
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3. Low quality rating: Double-downgraded 
randomized trials; or observational studies 
4. Very low quality rating: Triple-downgraded 
randomized trials; or downgraded 
observational studies; or case series/case 
reports. 
The GRADE evidence approach has figured largely in 
the Agency for Healthcare Research and Quality 
Methods Guide for Comparative Effectiveness 
Research to support the Evidence-base Practice 
Center (EPC) Program 26 . The EPC framework grades 
the strength of evidence from RCTs as well as 
observational studies in a systematic review through 
assessing specific domains: study limitations, 
directness, consistency, precision and reporting bias. 
Potential additional domains are: dose-response 
association, plausible confounding for observed 
effect and strength of association. Scoring these 
domains yields four strength of evidence grades: 
1. High: The reviewers are very confident that 
the estimate of effect lies close to the true 
effect 
2. Moderate: The reviewers are moderately 
confident that the estimate of effect lies 
close to the true effect 
3. Low: The reviewers have limited confidence 
that the estimate of effect lies close to the 
true effect 
4. Insufficient: The reviewers have no 
evidence, they are unable to estimate an 
effect, or we have no confidence in the 
estimate of effect for this outcome 
(e) NCCN Evidence Hierarchy 
Given the focus on cancer in claims made for NGS 
platforms, the evidence standards applied by the 
National Comprehensive Cancer Network (NCCN) to 
support guidelines recommendations should be 
noted 27. Each recommendation is evaluated by a 
panel and the strength of evidence (potentially for a 
specific NGS test) is identified using the NCCN 
Categories of Evidence and Consensus. While the 
goal is to base recommendations on high quality 
evidence from controlled clinical trials, meta-
analyses, studies for combination therapies, 
treatment sequencing and head-to-head studies are 
often not available. Panels may then use lower level 
evidence. The category recommendations are: 
Category 1: Based upon high-level evidence, there is 
uniform NCCN consensus that the intervention is 
appropriate; 
Category 2A: Based upon lower-level evidence, there 
is uniform NCCN consensus that the intervention is 
appropriate; 
Category 2B: Based upon lower level evidence, there 
in NCCN consensus that the intervention is 
appropriate; and 
Category 3: Based upon any level of evidence, there 
is major NCCN disagreement that the intervention is 
appropriate. 
All recommendations are 2A unless otherwise noted  
The importance of evidence standards in precision medicine 
claims should not be understated. If the application of NGS 
(and presumably the generations after that) is to be accepted 
it is crucial that we have publicly accessible, comprehensive, 
structured, transparent and bias-free evidence that support 
both claims development from analytical and clinical 
validations but subsequent clinical utility claims; claims that 
are credible, evaluable and replicable. Comparative and 
systematic reviews are central to this process: comparative 
because the choice of a test and a belief in the validity of the 
test is critical to its acceptance by treating physicians as an 
integral part of the process of care, and systematic because 
we require the accumulation of evidence from well 
conducted and credible effectiveness studies to support 
patient involvement in treatment decisions.  
If the hope is that a specific NGS platform be recognized and 
included as an element in a treatment guideline, then the 
NCCN standards should be built into any research program to 
support that platform. 
It is essential to recognize and accommodate the dynamic 
nature of NGS test development. Test platforms are typically 
in a process of continual upgrading as new evidence is 
presented for linkages, pathways and targeted therapies. To 
support this process manufacturers should be asked (possibly 
as part of annual or bi-annual test reviews) to confirm test 
performance as part of an ongoing process of re-evaluation 
and replication in target populations.  
Master Protocol Trials 
The standards proposed by GRADE and EPC for the evaluation 
individual trials and systematic reviews apply not only to the 
phase 2/3 classical randomized controlled trials in drug 
development and post market entry phase 4 effectiveness 
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trials, but apply with equal force to the trials directed to 
supporting evidence claims in precision medicine. These so-
called master protocol trials include basket trials, umbrella 
trials, hybrid trials and platform trials 28  .  These trial designs 
have been prompted by the heterogeneity that exists 
between patients within, for example, a given tumor type and 
also the heterogeneity that exists within an individual with 
tumor evolution and metastasis.  
Master protocols are an essential part of the process of 
translating molecular evaluation and genomic target 
matching into clinically relevant outcomes 29. These targets 
include both on-label and off-label prescription of approved 
compounds as well approval of investigational compounds 
developed as a result of NGS tests. While off-label matching is 
suggestive, ad hoc claims from clinical practice and 
systematic reviews of the literature are no substitute for trial 
based assessments. 
A credible and replicable evidence base driven by master 
protocols is also a potentially significant contributor to 
identifying the appropriate target mutation pathway. A test 
potentially identifies relevant multiple molecular aberrations 
by disease stage. This drives the choice faced by the treating 
physician in options for actionable single drug or multiple 
drug combinations. Faced with a number of potentially 
competing therapies that match to a mutation, prior 
assessment may also suggest an optimal treatment to 
support prognostic claims. Indeed, in the early stages of NGS 
platform modelling, the most important contribution may be 
to suggesting a hierarchy of target drug and drug 
combinations for master protocol trials.  
Understandably, in the absence of a well-documented, high 
quality and coherent evidence base, physicians and patients 
will be reluctant implement NGS recommendations.  
Prognostic claims that match mutation to therapy are no 
different in principal from classical drug claims. They should 
not be taken at face value. One of roles of a health system is 
to act as gatekeeper to ensure that these claims merit 
attention in clinical practice. This applies not only to the NGS 
test overall but to the individual prognostic claims. After all, 
support for one prognostic claim may be obscured by 
indifferent results for other prognostic claims within the 
proposed set of mutation and therapy linkages. Capturing 
heterogeneity is no guarantee of test performance for the 
individual therapy pathways.  
The common element in master protocol trials is to utilize a 
centralized screening test platform with a common protocol 
format for biomarker-driven sub-studies within the target 
population. This allows multiple parallel drug studies that 
replace the traditional (time consuming and wasteful) 
independent classical single target phase 1 through 3 
structures where a strong sub-group effect can be masked by 
a weak overall effect. In classical trial implementation post 
facto identification of sub-groups usually generates 
suggestions rather than hypotheses as the sub-sample is 
typically underpowered. In master protocol designs the sub-
studies can be flexible in their design to include multi-phase 
designs to match experimental drugs or the standard of care. 
The ultimate objective is to confirm the predictive role of the 
biomarker. 
Basket Trial Designs 
A basket trial is a master protocol where patient eligibility is 
defined by the presence of a particular biomarker or 
alteration rather than, for example, a particular cancer type. 
The claim is that response can be predicted from a tumor’s 
molecular characteristics matched to a target therapy (or 
therapies) independent of the tumor histology. As the 
standard of care will vary across tumor types, it is unusual to 
find a standard of care control arm. 
The principal objection to the basket trial design, at least 
from the perspective of a formulary committee, is that it says 
nothing about the overall benefits of introducing that test 
into clinical practice within single types or classes of cancer 
for target populations by stage of disease. From the 
perspective of overall clinical benefit and the potential cost-
effectiveness of the target therapy the evidence is incomplete 
and may, in fact, be misleading in failing to capture potential 
interactions between target therapies in patient groups.  
Umbrella Trial Designs 
In contrast to the basket trial, an umbrella trial focuses on a 
single type or class of cancers. The tumor is centrally 
screened and patients are assigned to molecularly defined 
sub-groups where they can be randomized and matched 
against the standard of care pathway. The presence of a 
single test, the randomization to target therapies and the 
standard of care for sub-trials, together with the ability to 
establish response, potential interactions, the impact of 
comorbidities and demographic factors within a guideline 
recommended treatment pathway for a specific cancer 
makes the umbrella trial attractive to formulary committees. 
Again, however, the formulary committee will need to be 
assured that the test is accurate and has been evaluated 
against comparator tests in agree target populations. 
 
 
Platform and Hybrid Trial Designs 
Platform designs are a randomized design with a common 
control arm and experimental arms defined by molecular 
type. Management of the platform allows therapies to be 
added or dropped through adaptive randomization to reduce 
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overall sample size and improve efficiency. Again, unless the 
platform design captures the range of biomarkers and 
manages therapies against those biomarkers, it is difficult to 
see the attraction of this design to formulary committees. A 
hybrid trial is one where there is a mix of umbrella and basket 
designs capturing combinations of histologies and molecular 
aberrations.   
Although standards have yet to be agreed for the reporting 
and assessment of master protocol trials, from the 
perspective of test choice, the umbrella trial is of particular 
interest. However, the results of a single umbrella trial only 
reflect the ability of the test to assign patients to molecular 
sub-types. Claims for the performance of target therapies 
against the standard of care will depend on the performance 
of the test against comparator tests in the accuracy of patient 
assignment and the ability of the test to match potentially 
high response therapies to those molecular markers.     
APPROVAL STATUS OF COMPETING TESTS 
It would be assumed by the formulary committee that the 
tests submitted (proposed and comparator tests) have been 
approved, either by the FDA or CMS or, given the present 
uncertainty over the responsible agency given the moves by 
the FDA to label tests as medical devices, a successor agency. 
 
The submission should detail whether the test has received 
regulatory or other approvals in the US or in overseas 
jurisdictions. Where approvals have been given the 
manufacturer should indicate whether the test: (i) has been 
approved only for specific targeted disease states; (ii) 
whether the material submitted to treating physicians has 
been approved by the regulatory agency (e.g., a restriction on 
reporting off-label variant matches); (iii) whether any 
restrictions or monitoring requirements have been required 
by a regulatory agency for toxicity or adverse events; and (iv) 
whether the test has been approved for inclusion in a 
professionally recognized treatment guideline (e.g., to meet 
NCCN recommendation standards). 
 
TARGET POPULATION FOR THE TEST 
As describe below in the context of the FDA reference 
standard for diagnostic tests, the target population for any 
NGS test assessment must be a target population that meets 
commonly accepted clinical and diagnostic criteria. If the 
target group is represented by the stage of disease, then 
recruitment to the target group for NGS evaluation and 
claims evaluation must conform to that definition. This allows 
both for comparisons between claims in that target 
population from competing tests as well as replication of 
claims made for that target population in other health 
jurisdictions. It is most unlikely (and inadvisable) for a health 
system to give the developer or vendor of an NGS test an 
‘open season’ remit to market the test across target patient 
groups (or ad hoc patients) in different disease states.  
 
As will be detailed below, the test has to be considered from 
the perspective of the anticipated benefits and costs that it 
confers on the target treating population within a specific 
disease state. Approval for a test to be reimbursed should be 
disease state specific. The approval should be linked to a 
management strategy where the test complements and is 
integral to initial diagnosis, disease staging and assessing 
relapse and resistance to the standard of care within that 
disease state. The criteria for introducing, interpreting and 
implementing a test and its recommendations should be 
detailed as part of the management strategy. 
 
To date, the FDA has endorsed a number of companion 
diagnostics where the target population is well defined. 
However, in many cases the claims for the test are much 
wider, arguing for example that test is appropriate across a 
number of disease states (e.g., small population non-
responsive cancers).  
 
The promise of NGS tests is, of course, only a first step to the 
acceptance of a particular test type as an integral and 
reimbursed element in the standard of care for specific 
cancer types and other diseases. Claims, for example, for 
maximal inhibition of viability and proliferation in tumor 
endpoints, and increased apoptotic effect need to be 
translated to claims for survivorship, toxicity and quality of 
life.  
 
Acceptance will also depend upon cost; the cost of the test, 
how often the test needs to be repeated over the course of 
the disease, the costs of the targeted drug therapies (which 
may change following future tests as a target tumor mutates) 
and the anticipated direct medical costs of supporting the 
patient over their lifetime. At the same time, the choice of 
test should be considered in comparative terms: if there are 
competing tests which claim a more robust evaluation and 
validation for target drug options their claims need to be set 
alongside those for the submitted test.  
 
Finally, to add a further level of complexity, there is the 
question of comorbidities. Older patients, typically those with 
cancers, will typically present with one or more 
comorbidities. The questions then become, first, one of 
asking whether the test takes into account the presence of 
comorbidities and, second, whether their management 
qualifies the claims made for cost and survivorship for the 
cancer target.  
 
The data set to describe the target population should include: 
• Selection Criteria: Clinical and diagnostic criteria for 
target patient population 
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• Epidemiology: prevalence and incidence estimates 
for the target population defined by place in therapy 
or stage of disease defining initial test application 
• Demographics: age, gender, ethnicity 
• Genetics: distribution of variants  
• Insurance status: Medicare, Medicaid, Veterans 
Administration, commercial 
• Comorbidities: prevalence of comorbidities by type 
and, if appropriate, by the stage of comorbid disease 
• Uptake: evidence for uptake or anticipated uptake of 
test (and comparator tests) to include tests sold in 
the previous two calendar years 
• Implementation: evidence for implementation of 
test recommended or proposed drug regimen (or 
regimens) 
• Guidelines: recommended treatment guidelines 
(e.g., NCCN) 
ANALYTICAL AND CLINICAL EVALUATIONS OF THE NGS TEST 
In presenting evidence for the technical merits of the NGS 
test it is important that the submission makes the distinction 
between evidence to support its analytical validity and 
evidence for its clinical validity. The former refers to the test’s 
ability accurately and reliably to detect variants (e.g., 
mutations, copy number variations) when they are present 
while the latter refers to the ability of the test to associate 
the variant with the presence or absence of the target 
phenotype. Thus, for DNA tests analytic validity requires 
establishing the probability that the test will be positive when 
a particular sequence of analyte is present (analytic 
sensitivity) or the probability it will be negative when 
sequence is absent (analytical specificity). The accuracy and 
reliability of the test, through replication in patient samples, 
is critical. 
 
Similarly, the assessment of clinical validity rests upon 
sensitivity and specificity, but with an assessment of positive 
and negative predictive values, with account taken of 
prevalence, potential heterogeneity and penetrance. Once 
again, the issue is one of accuracy: is the genetic variant (or 
variants) being analyzed related to the presence or risk of the 
target disease.  
 
Quality standards for laboratory testing performed on 
specimens from humans for the purpose of diagnosis, 
prevention, treatment of disease or assessment of health are 
established under the Clinical Laboratory Improvement 
Amendments (CLIA) of 1988 (as amended in 1997 and 2012). 
The CLIA covers the certification and oversight of clinical 
laboratory testing through federal regulations titled 
‘Standards and Certification: Laboratory Requirements’ (42 
CFR 493) issued by the Centers for Medicare and Medicaid 
Services (CMS). The CMS, under CLIA, oversees laboratory 
processes, not the tests they develop. There is no 
requirement for a premarket review of a test or for evidence 
of clinical validity. 
 
In October 2014 the Food and Drug Administration (FDA) 
published a draft guidance for the oversight of laboratory 
developed tests (LDTs). It was proposed that the FDA would 
oversee the quality of these tests alongside CMS. Given some 
confusion over the respective roles of the FDA and CMS with 
potential duplication an interagency taskforce was set up to 
collaborate on the oversight of LDTs. The position taken by 
the FDA is that its oversight will assure the tests are 
analytically and clinically valid. The taskforce has yet to 
report. 
    
If the proposed FDA framework is accepted CMS through CLIA 
will ensure quality through its focus on laboratory operations 
and the testing process while the FDA will contribute to 
quality standards by enforcing compliance with the agency’s 
quality systems regulation of the design and manufacture of, 
in this case NGS tests. The FDA view is that NGS tests are best 
considered as medical devices. Under section 201(h) of the 
Federal Food Drug and Cosmetic (FD&C) Act a product will be 
regulated as a medical device and is subject to premarketing 
and post-marketing regulatory controls if it is 
 
• An instrument, apparatus, implement, machine, 
contrivance, implant, in vitro reagent, or other 
similar or related article, including a component part 
or accessory which is: 
o recognized in the official National 
Formulary, or United States 
Pharmacopoeia, or any supplement to them 
o intended for use in the diagnosis of disease 
or other conditions, or in the cure, 
mitigation, treatment or prevention of 
disease, in man or other animals, or 
o intended to affect the structure or any 
function of the body of man or other 
animals, and which does not achieve its 
primary intended purposes through 
chemical action within or on the body of 
man or other animals and which is not 
dependent upon being metabolized for the 
achievement of any of its primary intended 
purposes.  
It is unclear how the Food and Drug Administration (FDA) will, 
if given jurisdiction, regulate NGS tests. At the present time 
there are an estimated 60,000 genetic testing products on 
the US market. Of these, the current estimate is that some 
7,600 would be considered high risk by the FDA. While there 
is debate (and pushback from the industry) as to the 
statutory authority of the FDA to regulate laboratory 
developed tests as medical devices, the balance of the 
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evidence appears to favor the FDA having jurisdiction. In a 
presentation to Congress in late 2015, Jeffrey Schulen, 
Director, Center for Devices and Radiological Health at the 
FDA,  argued that the FDA has jurisdiction over diagnostic 
tests under the flexible, risk-based framework established 
under the Medical Devices Amendments of 1976 (MDA) 30. 
Under this amendment the FDA assigns in vitro diagnostic 
devices (IVDs) to one of three classes that correspond to the 
level of risk the IVD presents to patients and the public 
(Classes I through III). In Class III IVDs (where in vitro NGS 
tests are likely to be assigned), the IVD presents the highest 
level of risk and should be subject to premarket approval, 
post-market and other controls to ensure the tests can be 
used safely and effectively. The primary risk of is that of an 
undetected inaccurate test result resulting from both false 
negatives and false positives. The former could lead to 
unnecessary or the delay of necessary medical procedures – 
including a false positive flag for a repositioned or new drug 
regimen; the latter equally could lead to injury or death from 
the unchecked progression of disease. Both, as Schulen 
points out, could lead to unnecessary costs. Among the tests 
that the FDA considers high risk are those for companion 
diagnostics. Presumably, the concern for injury and death 
could apply equally well to the therapy options matched by 
the NGS platform to mutations or mutation clusters. 
 
To ensure a reasonable assurance of safety and effectiveness, 
the benefits of a test will have to outweigh the risks it poses 
and that it will provide clinically significant results. For 
premarket approval there needs to be an independent 
demonstration of safety and effectiveness. The test has to 
achieve (i) a satisfactory analytical performance or validity in 
detecting pre-specified markers and (ii) a satisfactory clinical 
performance or validity demonstrating that the marker has a 
clinical significance in correlating with a disease or condition 
or with the ability to predict a therapeutic response to a drug.  
 
Most tests under Class III would need 501(k) clearance. 
The evidence presented to support analytical and clinical 
validity should conform to standards in place or standards 
proposed by the Food and Drug Administration (FDA). While 
these standards (and those presently proposed as guidance) 
apply to medical devices, those making the submission (or 
developing an NGS test) should assume, in the absence of 
agreed standards and processes, that the test will be 
considered a medical device for the purpose of the health  
system assessors.  
 
Molecular Diagnostic Services Program (MolDx) 
In 2011 CMS contracted to establish the Molecular Diagnostic 
Services Program (MolDx) through Palmetto GBA 31. The 
purpose of this program was to: 
• establish a unique registration identification of 
molecular diagnostics tests to facilitate claims 
processing and track utilization 
• to establish clinical utility expectations 
• to complete technical assessments of published test 
data to determine clinical utility and coverage 
• establish reimbursement for gene and gene 
components that meet Medicare covered service 
criteria 
As of October 2016, MolDx had approved 152 tests for gene 
and gene components that met Medicare criteria for a 
covered service. 
 
The clinical test evaluation process is in two parts (i) the 
evaluation of analytical and clinical validity and (ii) the 
evaluation of clinical utility 32. To meet Medicare ‘necessary 
and reasonable criteria’ the test must meet both evaluation 
standards. Performance standards have been established by 
MolDx for analytical validity. These include analytical 
specifications for comprehensive genomic profiling 33, 
analytical specifications for qualitative tumor only somatic 
variant detection using circulating tumor DNA.  
 
The fact that a test has met the standards for the medical 
necessity review and registration under the Molecular 
Diagnostic Services Program (MolDx) – and consequently 
received national coverage by Medicare – does not mean that 
those making the submission can put evidence for analytical 
and clinical validity to one side. Although it is not the policy of 
the MolDx to comment on failed applications, it is important 
to advise on whether the application for this test has been 
put to one side. 
 
When evaluating claims for clinical utility The MolDx team 
reviews each clinical trial presented to support claims for 
clinical utility. The trial data, to demonstrate the strongest 
clinical utility trial as opposed to other trials are classified as: 
(1) mCTD3A: A randomized prospectively controlled trial 
that directly demonstrates that a therapeutic 
intervention based on test results leads to 
statistically and clinically significant improvement in 
patient outcomes compared to currently accepted 
standard of care. 
(2) mCTD3B: A prospective-retrospective trial using 
archived samples from a previously reported 
prospectively controlled trial to demonstrate that 
treatment based on a molecular test result in a 
specified patient population is associated with 
improved outcomes in a statistically and clinically 
significant manner versus a currently accepted 
standard of care. 
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(3) mCTD2A: A prospective observational study 
enrolling patients in a registry, treating according to 
a defined pathway using a molecular test as an 
integral part of a care plan and demonstrating 
statistically and clinically significant improvement in 
healthcare outcomes versus a currently accepted 
standard of care. 
(4) mCTB2B: Retrospective data modelling using large 
data sets to demonstrate statistically and clinically 
significant improvement in healthcare outcomes 
when a given molecular test guides treatment versus 
a standard of care. 
(5) mCTD1; Retrospective observational studies that do 
not stipulate treatment pathways or follow-up 
results based on results from the molecular test 
(6) mCTD0: Preclinical studies where the data are from 
animal or in vivo experiments or related studies or 
trials  
If the level of evidence presented is below mCTD2B then the 
application will be rejected; although it is not clear what 
happens if the evidence based presented includes a mix of 
studies or where pre-clinical studies are linked to accepted 
studies. 
 
Prospective FDA Standards for NGS Tests as a Medical 
Device 
In July 2016 the FDA issued a draft (i.e., non- binding) 
guidance for regulatory oversight of NGS sequencing in vitro 
diagnostics 34. While draft guidance was directed to whole 
exome DNA sequencing or targeted DNA sequencing NGS-
based tests for diagnosing germline diseases or other 
conditions arising from inherited or de novo germline 
variants, the standards required are indicative of those the 
FDA might propose for somatic diseases. The 
recommendations cover (i) the design, development and 
validation of NGS-based tests and (ii) FDA-recognized 
standards for regulatory oversight of those tests.  
 
It should also be noted that the FDA already has in place 
standards for evaluating diagnostic tests 35  . This guidance is 
intended for the submission of premarket notification 
(510(k)) and premarket approval for diagnostic devices or 
tests where there two possible outcomes: positive or 
negative. These standards are important because they 
provide more detail on benchmarks for assessing diagnostic 
performance. The benchmarks are: (i) comparison to a 
reference standard defined as the ‘best available method for 
establishing the presence or absence of the target condition’; 
and (ii) non-reference standards. The benchmark will 
determine which performance measures are appropriate.  
 
Reference standards are those agreed and adopted by 
‘opinion or practice within the medical, laboratory or medical 
community’. This distinction is important in precision 
medicine as it points to the importance of a consensus 
opinion in defining target patient groups for reporting clinical 
trial results and for the assessment of prognostic claims from 
NGS tests. The FDA recommends that before proceeding they 
should be consulted to ensure the reference standard meets 
the agency needs. 
 
Even so, these standards are a long way from standards for 
NGS tests. Meeting standards for analytical and clinical 
validity are only a necessary, not a sufficient condition for 
approval of an NGS test as a medical device. The issue which 
is probably most vexing is how to evaluate the merits of 
competing tests. If NGS platforms generate different outputs, 
then the FDA should possibly consider minimum response 
standards at both the aggregate and pathway level (in effect 
to weed out the ‘duds’ and tests which have a high 
proportion of ‘duds’). It seems possibly unreasonable to put 
the burden on health care systems; so perhaps, if the FDA 
adopts a more laissez faire approach, the onus should be (as 
is proposed here) for test developers and vendors to make 
the comparative case for their product. 
 
It is worth emphasizing the FDA perspective as it raises the 
questions that an assessment by health care decision makers 
should address as an NGS-based test for clinical use will 
typically include reagents, consumables, instruments and 
software. The presence of one or more of these will be 
dictated by the workflow and functioning of the test. It is 
important, therefore, to detail the steps in the test process. 
These may include: (i) specimen collection and acceptable 
types for processing and storage; (ii) DNA extraction; (iii) DNA 
processing and library preparation; (iv) the regions of the 
genome, including genes and variants, that are interrogated 
by the test; (v) generation of sequence reads and base calling; 
(v) variant classification/interpretation and (vi) preparation of 
test report.  
 
At the same time, the test may involve manual variant 
interpretation. If this is the case then the technical 
description should include standard operating procedures 
(SOPs), decision algorithms and supplementary test 
components.  
 
It is important that the submission, in particular for tests 
supporting next generation sequencing, includes a technical 
description of the predictive platform. Consider predictive 
simulation modeling, for example, where an in silico platform 
incorporates integrated networks of signaling and metabolic 
pathways through aggregating functional relationships 
between proteins and predicts mechanisms using drug 
combinations that interact to reduce viability, proliferation 
and other endpoints through the creation of patient avatars 
36. The platform needs to be described and should include, in 
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this instance, how the effects of drugs or drug combinations 
are selected and applied from a library of molecularly 
targeted drugs to short-list potential repurposed or novel 
drug candidates.  
 
Information should also be provided on how the library is 
curated, aggregated and interpreted in evaluating linkages. 
Although there is no requirement here that the library or, as 
described by the FDA, a ‘genetic variant database’ should be 
publicly available, the standards proposed for recognition by 
the FDA of a genetic variant database as a source of valid 
scientific information to support claims for the analytical and 
clinical performance of a test should be met. Two standard 
operating procedures are critical: 
• procedures for the curating, aggregating and 
interpretation of high quality valid scientific 
evidence to support claims for the analytical and 
clinical performance of the platform 
• procedures for updating inputs and maintaining the 
stability and architecture of the platform content 
and processes 
If the test manufacturer employs third parties to collect 
samples and undertake assessments, the role of these should 
be identified 
 
Possible FDA Requirements in Developing an NGS Test 
Design considerations in developing an NGS test (or reporting 
on a developed test) focus on the activities that the 
developer should have performed to identify the intended 
clinical use of the test and to design the test for that use. 
Developers should establish and justify minimum acceptable 
and target values for each performance metric appropriate to 
the indications for that use (e.g., define clinical need that is 
driving test development, justify required test features, 
specify specimen types, identify required metrics and 
threshold performance standards). All test components and 
methods should be identified to include sequencing platform 
and controls. 
 
The developer should identify and report on test analytical 
performance characteristics for the predefined metrics to 
ensure the test successfully identifies, within statistical 
bounds, the presence or absence of a variant. At the same 
time, once the test is in clinical use it should be continuously 
monitored. The draft guidance suggests a set of performance 
metrics for (a) accuracy with thresholds for positive percent 
agreement, negative percent agreement, technical positive 
predictive value and the rate of ‘no calls’ or ‘invalid’ calls; (b) 
precision - reproducibility and repeatability – for variant and 
wild type calls; (c) limit of detection for each variant type; and 
(d) analytical specificity – interference, cross reactivity and 
cross-contamination.  
 
The developer should also establish minimum acceptable 
thresholds for test run quality metrics.  To determine 
whether a test run or variant call may need supplemental 
procedures to query further a variant call.  
 
From the perspective of a formulary committee or health 
system evaluating the merits of an approved NGS test or 
competing tests, the draft guidance also suggests information 
be posted to the public domain (e.g., a manufacturer’s 
website) to cover: 
(i) Test performance 
(ii) Test design 
(iii) Test reports  
Information on Test Performance 
When reporting on test performance, the draft guidance 
recommends that the following information be posted in the 
public domain: 
• Indications for use 
o Type(s) of sequence variations 
detected 
o Any test limitations (erg., variants the 
test cannot detect) 
o The fraction of an affected population 
for which the test is likely to provide 
relevant results  
• Regions of the genome in which sequences 
meeting pre-performance specifications can be 
identified relevant results 
• Types of variants the test will report 
• For targeted panels list the gene(s) included in 
panel 
• For whole exome sequencing (WES) based tests 
to describe clinically relevant regions of the 
exome and relevant coverage for those regions 
• For summary performance 
o Results for test accuracy/precision 
o Results of reproducibility studies 
o Results for targeted panels 
o Results for WES 
• Test failure 
o Probability of failure from performance 
data 
o Scenarios under which the test can fail 
Information on Test Design 
Again, this should be posted to the public domain: 
• Specify test components 
• Describe steps in test design 
• Details on specimen type 
• Minimum DNA yield and quality 
• Method for sequencing DNA 
• Level of multiplexing (if applicable) 
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• Specify all software components 
• Detail databases used for analysis 
• Criteria for annotation and filtering of variants 
Information for Test Reports 
Also published to the public domain: 
• Relationship between reported variants and the 
clinical presentation of the patient 
• Description of the genomic and chromosomal 
regions detected by the test 
• Summary of test performance studies  
• List of pathogenic or actionable variants 
(including those of unknown significance) 
o Variants to be reported using common 
nomenclature 
o Description of clinical evidence 
supporting the interpretation reported 
variants 
o Summary of genes related to the 
patient’s phenotype (with reference to 
databases for variant interpretation) 
o Additional information that may be 
required 
• Test limitations 
• Risk mitigation procedures (if required 
 
TREATMENT PATHWAY AND AGGREGATE PERFORMANCE 
CLAIMS 
As described briefly in the introduction to this commentary, a 
key distinction in validating claims for the reimbursement and 
placement of an NGS test is between (i) the overall 
performance of the test against the standard(s) of care that 
characterize the proposed intervention point for the test in 
the treatment pathway for a specific disease and (ii) the 
contribution of the most frequently recommended therapy 
combinations that the test administrator reports for the 
individual platform assessments. 
 
Competing claims for NGS tests will rest, therefore, on both 
aggregate performance and patient response at the therapy 
choice level. This distinction has a number of implications: (i) 
there is no certainty that different platforms will generate 
similar or the same therapy choice recommendations; (ii) 
adverse events and toxicity may differ between treatment 
pathways so that risk mitigation may be driven by pathway 
therapy choices; (iii) if drug-to-drug interactions are a 
concern, they are best explored at the pathway level; (iv) 
response to therapy may vary by therapy choice which may 
lead to qualifications of indication for use; (vi) resource 
utilization and cost claims may vary by therapy pathway so 
that the distribution of patients by therapy pathway may be a 
major, if not the principal, determinant of therapy costs; (vii) 
adherence and persistence with therapy may differ by 
pathway, suggesting possible pathway specific interventions 
to support therapy utilization; and (viii) the impact of 
comorbidities and their impact on the overall polytherapy 
burden may qualify response to therapy through adherence 
and persistence.  
 
COMPARATIVE NGS EVALUATIONS 
It is unlikely that a formulary committee or health system will 
only evaluate a single test. With the potential commercial 
benefits of test adoption, it is more than likely that decision 
makers will be faced with a number of competing tests. Given 
this, it is important that the information requested for each 
test is to a fixed standard that allows a comprehensive 
assessment of competing claims for clinical and analytical 
validity. 
 
In the unlikely event that there has been a head-to-head 
comparison of the analytical and clinical validity of the 
proposed test against one or more actual or potential 
comparator tests, a submission should include: 
(i) A summary statement of the clinical and 
analytical benefits of the proposed test over 
competing tests in the target population or 
for each of the populations indicated 
(ii) A detailed justification for the place of the 
proposed test and competing tests in the 
care pathway for the target disease state 
population (or populations) together with 
the clinical criteria for implementing the 
test 
(iii) A profile of the anticipated frequency with 
which the test and competing tests will be 
replicated to assess tumor progression and 
the clinical criteria for re-assessment  
(iv) A summary of test performance for the test 
and competing tests 
(v) A summary of test design for the test and 
competing tests 
(vi) Evaluation reports for the test and 
competing tests 
(vii) Procedures for reporting updating and 
monitoring of the test and competitors (if 
known) with implications for use and 
reporting of test results 
(viii) Procedures for risk mitigation and reporting 
for the test and competing tests 
Techniques for assessing the analytical validity of NGS tests 
need not be restricted to those data elements proposed in 
the FDA guidance. There are a range of possible tests that can 
supplement claims for sensitivity and specificity and 
prevalence corrected claims for positive and negative 
predictive value with the appropriate confidence intervals.  
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INTEGRATION IN CARE PATHWAYS 
To date, there are only a few treatment guidelines that have 
included the option of genomic testing as an element in care 
pathway decisions. As claims for the introduction of NGS tests 
as an integral part of the process of care will likely run ahead 
of their introduction into treatment guideless, it is important 
that those proposing a role for NGS in disease states (by stage 
of disease for a target population) present a robust, evidence-
based case for the test (e.g., to meet NCCN standards).  
 
The test submission should detail, for each disease state, the 
potential placement of the test in the process of care 
together with a consensus definition on the target 
intervention group. Given the focus of precision medicine on 
cancer, in particular late stage cancer interventions, 
submissions should utilize as their template for test 
placement in oncology the treatment pathways and clinical 
guidance developed by the NCCN 37 In non-oncological 
disease states the guidelines should be latest proposed by the 
respective professional associations.  
 
While it is unlikely that a professional group responsible for 
treatment guideline development would nominate a 
particular NGS test, it is possible that they would set the 
minimum performance standards required for an NGS test to 
be accepted into clinical practice for target patient 
populations. 
 
The appropriateness, acceptance or otherwise of claims for 
the analytical and clinical validity of an NGS test are only 
relevant in the context of the ‘footprint’ of the test. Is the test 
designed to: 
(i) apply across the board to a range (or any number) of 
disease states 
(ii) apply to a single disease state 
(iii)  apply to a target tumor across a range (or any 
number) of disease states 
(iv)  apply to a target tumor in a single disease state 
Each of these footprints should be supported by an evidence 
base which meets the standards for the quality of the 
evidence as well as claims for the test which are credible, 
evaluable and replicable in the restive molecular targets. This 
is seen in the case of the footprint (i) where the claim is for 
the test across either ‘any’ disease state or for a sub-set of 
disease states. 
 Irrespective of the breadth of the claim, a formulary 
committee is faced with the question of whether limited 
claims for the test in a sub-set of disease states can be 
assumed to be sufficient to accept the test as the basis for 
molecular targeting in disease states where the evidence is 
lacking. Clearly, it would be unwise, given issues of 
performance and safety outcomes, to assume that this is the 
case. Formulary committee, therefore, should request 
substantive and credible evidence for claims in each disease 
state. This should apply to claims directed towards the test’s 
target population by stage of disease. 
 
An important caveat is the whether the test utilized in a 
particular trial design is the test proposed by a vendor for 
approval by the health care system. Claims for analytical and 
clinical validity are only acceptable if the claims for analytical 
and clinical validity between competing tests to identify one 
or more molecular targets and link these to proposed therapy 
interventions are compatible for all target treating 
populations within the test ‘footprint’.  
 
No test can claim to have identified all potential molecular 
markers and the potential interactions between variants with 
their impact on patient response. Even within a given 
histologic tumor multiple markers may be present.  
In the unlikely event that a manufacturer underwrites a head-
to-head comparison with competing tests or at least the most 
likely comparator for a target population in one or more 
disease states, an assessment of competing claims will rely 
upon indirect comparisons. While this is a common situation 
in drug product evaluations, where there is an established 
methodological literature to support indirect comparisons, 
comparing competing tests adds a further level of complexity.  
 
Unless an effective indirect comparison between competing 
tests is undertaken, payers have no basis for assessing the 
merits of claims made by a developer/vendor. This situation 
is made more difficult given the footprints of competing tests 
and the number of tests that will be competing for the 
attention of payers. Even with common agreement on 
analytical and clinical validity standards in the case, for 
example, where a test is considered a medical device and the 
FDA takes responsibility for class III 501(k) evaluations, there 
is no certainty that competing tests will generate similar 
variant profiles for therapy interventions. This is a situation 
which will make indirect comparisons more complex if there 
are options for matching therapies to specific variants given 
individual NGS test results.  
 
EVIDENCE BASE FOR NGS TESTS 
At the present time, while there is accumulating evidence for 
the analytical and clinical validity of NGS tests, although 
minimum performance standards for accuracy have yet to be 
agreed, there is little evidence from either randomized 
clinical trials or well conducted observational studies. 
Formulary committees and other health decision makers are 
understandably reluctant to support a specific NGS test not 
only with the absence of, for example, umbrella trial designs 
matching test results against the standard of care in target 
populations but, equally importantly, comparative 
assessments of competing tests. 
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Randomized Clinical Trials 
Required performance criteria for NGS tests in target patient 
populations are no different from the criteria that would 
apply to non-NGS treatment options. The test would be 
judged in comparative terms against the outcomes that are 
typically applied in therapy impact assessments within that 
disease group and by stage of disease.  
 
In late stage oncology interventions where there are a range 
of potential roles for NGS evaluations and their contribution 
to the process of care, clinical standards for outcomes are 
well established. These capture both the primary outcomes 
these outcomes – progression-free survival, overall survival, 
relapse, toxicity – and secondary endpoints that focus on 
patient reported outcomes, including functional status, pain 
and both generic and disease specific quality of life measures.  
 
Given that the adoption of NGS tests is at any early stage and 
that the evidence base to support disease and target-group 
specific NGS claims is limited, developers of NGS tests face 
three hurdles. First, to invest in well-designed randomized 
clinical trials to compare NGS interventions against the 
standard of care in target disease states; second, to develop 
protocols to validate claims in treatment practice; and, third, 
to develop a robust methodology to compare the 
effectiveness of competing NGS tests. 
 
Although standards for randomized clinical trials are well 
established, the NGS trial design is necessarily challenged by 
heterogeneity within patient populations. It is important to 
recognize the diversity of trial designs that have been 
proposed under the overall ‘umbrella’ designation to account 
for (i) inter and intra patient tumor molecular heterogeneity 
and (ii) tumor progression and the capture of intra-patient 
heterogeneity over time 38. There is a developing literature 
and examples of alternative umbrella trial designs (e.g., the 
PANGEA IMBBP Phase1/2 trial design for gastro-esophageal 
adenocarcinoma) 39 . Given the complexity of these designs in 
terms of both treatment pathways, definition of standard of 
care, target drug combinations and variations in the incidence 
of biomarkers from exome sequencing in target trial 
populations, the structure of the various trials needs to be 
adequately described. When the results of trials are reported 
they should reference claims for analytical and clinical validity 
to support the structure of the trial and the individual 
therapy pathways.  
 
Reporting randomized trials, required data elements: 
• Title and ClinicalTrials.gov identifier 
• Sponsor (and collaborator) 
• Study design 
• Disease diagnosis  
• Treatment guideline 
• Target population (including tumor type) 
• Inclusion/exclusion criteria 
• Assessment of tumor progression 
• Test for molecular profiling 
o Test platform 
o Test quality and approval status 
o Analytical and clinical validity 
• Patient biomarker (oncogene) distribution in 
target population 
• Tumor suppressor therapy distribution to define 
therapy pathways 
• Criteria for optimal pathway prognostic 
treatment choice 
• Clinically actionable oncogene-tumor suppressor 
groups distribution 
• Patient distribution by actionable oncogene-
tumor suppression groups 
• Primary endpoint measure(s) 
• Secondary endpoint measures 
• Trial structure and duration of therapy 
o Active arms (actionable tumor 
suppressor groups) 
o Control arm (standard of care) 
o Allocation 
o Criteria and/or timing for re-testing 
• Aggregate outcomes: primary endpoints  
• Aggregate outcomes: secondary endpoints 
• Pathway outcomes: primary endpoints 
• Pathway outcomes: primary endpoints 
• GRADE classification 
Systematic Reviews and Meta-analyses 
Submissions to support an NGS test submission to a health 
system or formulary committee should not rely upon one or 
two randomized trials. These should meet the PISMA-P 2015 
standards. The complexity of gene expression and the range 
of platforms utilized to identify recommended therapy 
options means that the greatest credibility will be afforded 
the test with the most credible evidence base.  
 
Submissions to formulary committees should report on a 
systematic review of all randomized trials for the specific test 
as well as for potentially competing tests. This sets the stage 
for indirect comparisons of competing NGS claims. Again, the 
systematic review should be restricted to the evidence for the 
target population. Given inter and intra patient genomic 
heterogeneity, it cannot be assumed that claims for the NGS 
test in one target population can be used to support 
prospective claims for efficacy or effectiveness in other target 
populations. Nor can it be assumed that test claims from 
trials reported for the target treating population, given 
molecular heterogeneity, need necessarily translate to the 
health system’s target population. At the same time there 
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needs to be a clear statement of the justification for an 
expected ‘optimal’ monotherapy or combination therapy 
choice to matching individual patients to their respective 
biomarkers.  
 
Observational Studies 
Observational studies include (i) prospective studies that are 
protocol driven and are intended to evaluate claims made 
from models and (ii) retrospective studies that are intended 
to evaluate claims from integrated databases. It is unlikely, at 
this time, that retrospective observational studies will play a 
substantive role in evaluating claims for specific NGS tests 
until integrated data sets expand the coverage to include 
identifiers for specific NGS tests and expand their capture of 
genomic information to include variant or mutation 
classifications. The most likely source of data will be from 
results reported for prospective observational studies that 
adhere to a protocol submitted in support of a specific NGS 
test. Indeed, the importance of evidence from protocol-
driven observational studies, compared to the costs and time 
involved in undertaking a randomized trial, will place a 
premium on developers or vendors of NGS tests to engage 
with health care systems to partner in prognostic claims 
validation within target populations. 
 
The purpose of the prospective protocol driven observational 
study is twofold: (i) to evaluate the claims made for the NGS-
directed therapy choices for both the targeted patient 
population and patients assigned to specific therapy groups 
as ‘individualized’ packages and (ii) to evaluate claims for 
resource utilization and, potentially, cost savings again for the 
targeted patient population and the therapy groups. 
 
The point to emphasize is that unless claims utilizing NGS 
tests can be validated by health care systems, there is no 
basis for reimbursement or an agreement on pricing. 
Randomized clinical phase 2 and phase 3 trials are a key 
input, but these need to be followed up with observational 
tracking studies within target patient groups. Accumulating 
evidence from tracking studies across similar target 
populations in health care systems will, hopefully, provide a 
robust and believable evidence base for the individual NGS 
platform.  
 
Reporting observational studies: required data elements: 
• Title  
• Sponsor (and collaborator) 
• Copy of study protocol 
• Target patient population 
• Criteria for selecting patient population 
• Criteria for selecting treatment pathways 
• Basis for claims to be assessed 
o Prospective model 
o Retrospective assessment 
• Model summary 
• Claims to be evaluated by selected 
treatment pathway 
o Clinical outcomes 
o Safety and toxicity 
o Remission and relapse 
o Survivorship 
o Quality of life 
o Pain 
o Patient satisfaction 
o Other patient reported outcomes 
o Resource utilization 
o Direct medical costs 
• Study implementation 
• Inclusion/exclusion criteria 
• Test for molecular profiling 
o Test platform 
o Test quality and approval status 
o Analytical and clinical validity 
• Patient biomarker (oncogene) distribution 
• Tumor suppressor therapy distribution 
• Criteria for optimal prognostic treatment choice 
• Clinically actionable oncogene-tumor suppressor 
groups distribution 
• Patient distribution by actionable oncogene-
tumor suppression groups 
• Treatment Pathways 
• Timelines 
• Adherence and persistence 
• Aggregate test outcomes 
• Treatment pathway outcomes 
• GRADE classification 
Modeled Study Claims 
Claims evaluation involving a protocol assessment will 
typically rely upon cost-effectiveness or cost-utility models. 
These would take a short term focus with the results reported 
in a timeframe relevant to decision makers. The model may 
be structured around a clinical trial or it may extrapolate from 
that trial. Claims generated by models are only acceptable if 
they are credible, evaluable and replicable. The structure of 
the model would probably replicate and extrapolate from the 
design of umbrella trials reporting for the particular NGS test. 
Treatment pathway criteria should be justified (e.g., high 
frequency therapy choice clusters). Inputs to the model 
would be based upon the results of the systematic review of 
the trial literature for that test together with those inputs 
from a review of the literature where trial primary and 
secondary outcomes fail to capture the particular parameter 
(e.g., specific patient reported outcomes such as quality of 
life).  
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Standards for model building are well established, to include 
the treatment of structural and parameter uncertainty 40. 
Care should be exercised, however, in adopting standards of 
the International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR) as these include study designs 
that are not intended to generate evaluable claims 41  42 43. 
 
It is expected that the modeled claims made for the NGS 
package in the targeted patient groups will be presented as 
part of the submission package (see below) by the NGS 
developer or vendor. Claims, both clinical and cost-effective 
(or cost-utility) would conform to the standards of normal 
science: they would be credible, evaluable and replicable. 
Unlike traditional cost-effectiveness claims, the claims 
proposed by the developer would be expected to take 
account of the tumor heterogeneity in the target population 
in the choice of treatment pathways to compare to 
standard(s) of care pathway(s).  
 
At the same time, however, a model would have to 
accommodate potential confounding factors such as the 
presence of co-morbidities, drug-to-drug interactions both 
between the tumor specific drugs as well as with those 
assigned for other conditions. Within the timeframe for the 
model, claims should attempt to accommodate adherence 
and persistence behavior, non-tumor related morbidity and 
mortality and anticipated responses involving possible re-
testing and drug therapy reallocation to accommodate tumor 
progression. The lifetime of the modeled claim will have to be 
consistent with ongoing reporting of outcomes to a formulary 
committee. Unless the anticipated timeframe for survivorship 
is ‘short’, lifetime cost-utility claims would be of no interest 
as they would lack credibility for evaluation and replication. 
 
Any modeled claim for NGS based-interventions has to be 
comparative. The model would then have to accommodate 
the standard of care reference point, together with (again 
over the lifetime of the model) interventions to 
accommodate the expected disease progression. In some 
instances, a developer or vendor may attempt to model 
competing platforms for the target population. Again, 
comparative claims would have to be credible and open to 
evaluation. 
 
NGS UPTAKE AND IMPLEMENTATION 
Modeling a claims for the anticipated impact of NGS platform 
indicated treatment pathways should also take account of (i) 
the uptake of the NGS test by the treating physicians (i.e., 
ordering the test) and (ii) the implementation of the test (i.e., 
following the recommended therapy pathways for matched 
patients). Evidence to date, admittedly anecdotal, would 
suggest that less than fifty per cent of treating physician 
order tests with even fewer actually attempting to implement 
the test results. At the same time, we have no data on 
patterns of adherence and persistence with a test-directed 
regimen. This situation is made more opaque by the absence 
of data on the monitoring of patient responses to a therapy 
choice and the criteria that physicians may follow to order 
further tests in response to patient relapse and the likelihood 
of adverse tumor progression. 
 
Reporting requirements should include:  
• Uptake of the NGS test within each target 
population group 
• Proportion of those requesting the NGS test that 
implement the test recommendations 
• Distribution of patients by NGS recommended 
therapy choice and standard(s) of care 
• Adherence and persistence with NGS 
recommended therapy choice for first six 
months following index prescription(s)  
• Additional NGS tests 
• Subsequent six monthly reports covering the 
preceding six months 
Requesting an NGS Test 
The request for an NGS test is the responsibility of the 
treating physician in consultation with the patient. The 
submission from the developer should include a pro forma of 
the information to be provided by the treating physician 
when the test is requested. As a minimum this should detail 
(i) patient demographics (age, gender, ethnicity); (ii) clinical 
assessment and stage of disease; (iii) comorbidities; and (iv) 
current drug regimens. On receipt of a request, the developer 
should inform the treating physician if FDA-mandated risk 
mitigation and reporting requirements are in place for any of 
the anticipated drug or drug combinations that are likely to 
be suggested for the individual within the target patient 
group. The FDA may, of course, put risk assessment 
requirements in place as a blanket requirement for the NGS 
test. 
 
Implementing NGS Test Results 
A question that has to be addressed with the advent of NGS is 
how the treating physician is to act on recommendations 
made for a repositioned FDA approved therapy for an 
individual patient. As it is unlikely that there will be a 
common repositioned therapy (or therapies) for those failing 
or non-responsive to the standard of care, one role of a 
formulary committee or health system in approving an NGS 
platform is to request developers for their recommendations 
for repositioning are to be translated into clinical practice 
decisions and how they would assess and report relative 
benefits/harms. The NGS developer should agree with the 
health system the content of reports to be provided to 
treating physicians to guide therapy options and report safety 
issues.   
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One approach that should be considered is the heuristic 
Oxford Centre for Evidence Based Medicine (OCEBM) levels 
that cover the entire range of clinical questions that a 
clinician might ask. The OCEBM system allows clinicians and 
patients to appraise evidence for prevalence, accuracy of 
diagnostic tests, prognosis, therapeutic effects, rare harms, 
common harms, and usefulness of (early) screening44 .  
 
Another and more recent approach is the GRADE Evidence to 
Decision (EtD) framework 45. This should be considered as a 
possible model for informing physicians and supporting 
clinical decisions. The EtD approach is to assist physicians to 
use evidence in a structured and transparent way, linking to 
practice guidelines and going from evidence to decision.  
 
Feedback on Test Performance 
The credibility of claims and agreement on the place of a 
specific NGS test in therapy across a number of disease states 
will require tracking outcomes to be reported back in a timely 
fashion to health care decision makers. The protocol that is 
drafted and agreed with the health system should detail the 
frequency and content of reports on the performance of the 
test. Confidence that NGS recommendations have a credible 
role in treatment decisions must be evidence based. They 
should be reported by the developer or vendor to the health 
care system. They should also be made available in the public 
domain through peer reviewed publications and web sites. It 
is important, therefore that the claims assessment protocol 
that is agreed with a health system details which claims are to 
be reported, how they are to be reported and the timeframe 
for reporting. 
 
THE NGS SUBMISSION 
Submissions to support NGS adoption should meet a common 
evidentiary standard. The following outline is proposed: 
 
I. Executive Summary 
• Place of the proposed NGS test in therapy 
• Anticipated benefits and harms 
II. Test Platform Specification 
III. Proposed Target Population(s) 
• Epidemiology 
• Demographics 
• Comorbidities 
• Test place in therapy 
• Criteria for test implementation 
• Guideline recommendations for genomic tests 
IV. Test Accuracy 
• Analytical validity 
• Clinical validity 
V. Test Processes and Reporting 
• Requesting the test 
• Test inputs 
• Processing test inputs 
• Reporting test results 
• Liaison with treating physician 
VI. Evidence Base for Test Claims 
• Randomized clinical trials 
• Observational studies 
• Outcomes in clinical practice 
• Test uptake and implementation in clinical 
practice 
VII. Clinical Claims for Test in Target Population(s) 
• Survivorship and relapse 
• Safety and toxicity 
• Quality of life 
• Other patient reported outcomes 
VIII. Modelled Cost-Outcomes Claims 
• Model structure 
• Model parameters 
• Model inputs 
• Uncertainty 
• Model claims 
IX. Claims Assessment Protocol 
• Agreement on Protocol and IRB Approvals 
• Claims to be evaluated 
• Risk mitigation 
• Timeframe 
• Target population 
• Recruitment 
• Monitoring and Quality Assessment 
• Reporting 
X. Reviewing the Test Platform and Claims 
• Agreement on regular reviews 
• Re-assessment of test claims 
APPENDIX A: Comparator NGS Tests: Approvals and 
Platforms 
APPENDIX B: Evidence Base Spreadsheet Summary: Proposed 
Test  
APPENDIX C: Evidence Base Spreadsheet Summary: 
Comparator NGS Test   
APPENDIX D: Targeted Claims Evaluation for Comparator 
Tests 
 
QUESTIONS A FORMULARY COMMITTEE SHOULD ASK 
Once a submission to support a NGS product is received, 
there are a number of questions that a formulary committee 
should ask (or included as a checklist as part of the 
submission). These questions relate to: (i) the proposed NGS 
test; (ii) the performance of the proposed NGS test in each of 
the target patient populations; and (iii) evidence for the 
proposed test and claims made against the standard of care 
for the target patient group and potential comparator NGS 
tests. The questions are detailed in Table 1: 
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TABLE 1 
  NEXT GENERATION SEQUENCING PRODUCT SUBMISSION: QUESTIONS A FORMULARY COMMITTEE SHOULD ASK 
Question 
No. 
Question Submission 
Section 
Response Y/N 
Comments 
1. Has the submission provided an executive summary that summarizes the place of 
the NGS test in therapy for the target populations for the test? 
I  
2. Has the executive summary summarized the anticipated benefits and harms for 
each of the target populations from the introduction of the NGS test? 
I  
3. Has the submission provided a technical specification of the NGS test to include 
meeting STARD 2015 and QUADAS-2 standards?  
II  
4. Has the technical specification of the test detailed the steps in the test process: 
(i) specimen collection, processing and storage; (iii) DNA extraction; (iv) DNA 
processing and library preparation; (v) regions of genome interrogated; (vi) 
generation of sequence reads and base calling; (vii) variant 
classification/interpretation; and (viii) preparation of test report.  
II  
5. Has the technical specification of the test detailed standard operating 
procedures for curating, aggregating and interpreting high quality valid scientific 
evidence for the analytical and clinical performance of the platform?  
II  
6. Has the technical specification of the test detailed standard operating 
procedures for updating inputs and maintaining the stability and architecture of 
the platform content and processes? 
II  
7. Has the test specification identified the roles of third parties in the collection and 
assessment of samples? 
II  
8. Has the test specification identified any manual variant interpretation? II  
9. Has the submission detailed the intended target populations for the test by 
disease type and by their place in therapy?  
III  
10. Has the submission provided a definition of each of the target population groups 
and their criteria for selection that meets national and international standards 
for clinical and diagnostic identification? 
IV  
11. Has the submission identified for each of the target population groups the place 
in therapy for the proposed genomic assessment given current treatment 
guidelines and treatment pathways? 
III  
12. Has the submission provided a profile of the target patient groups: (i) 
epidemiology; demographics; and (iii) comorbidities  
III  
13. Has the submission provided for each of the target patient populations the 
results of assessments of analytical validity to recommended FDA standards? 
IV  
14. Has the submission provided for each of the target patient populations the 
results of assessments of clinical validity to recommended FDA standards? 
IV  
15. Has the submission detailed how the results of the test will be reported to 
treating physicians? 
V  
16. Has the submission detailed how the results of the tests will be linked to 
recommendations for single and multiple therapy choices as alternatives to the 
standard of care? 
V  
17. Has the submission detailed how requests from treating physician requesting 
clarification on test results will be handled? 
V  
18. Does the submission meet the required evidence standards for reporting clinical 
trials and observational studies (PISMA- 2015 for systematic reviews, CONSORT 
and GRADE/EPC)?  
VI  
19. Has the submission provided a systematic review of randomized clinical trials, 
summary evidence tables and a commentary for efficacy and safety for the 
proposed NGS test in the respective target patient populations?  
VI  
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20. Has the submission provided a systematic review of observational studies, 
summary evidence tables and a commentary for efficacy and safety for the 
proposed NGS test in the respective target patient populations? 
VI  
21. Has the submission included a summary of the outcomes achieved in clinical 
practice for the individual target patient populations where the NGS test has 
been utilized? 
VI  
22. Has the submission provided a summary of the historical uptake of the NGS test 
in the individual target patient populations? 
Vi  
23. Has the submission provided credible, evaluable and replicable modeled claims 
for the anticipated benefits and risks from introducing the NGS test in the target 
patient populations? 
VII/VIII  
24. Do the modeled claims made for the NGS test in the target populations include 
(i) survivorship and relapse; (ii) safety and toxicity; (ii) quality of life; and (iv) 
other patient reported outcomes? 
VII/VIII  
25. Are the claims provided in the submission presented in comparative terms versus 
the standard of care? 
VII/VIII  
26. In presenting the modeled claims, are these modeled separately for each of the 
target populations and therapy pathways? 
VIII  
27. Has the submission provided details on: (i) model structure; (ii) model 
parameters; (iii) model input sources; (iv) treatment of uncertainty; and (v) 
incremental benefits for outcomes and costs versus standard of care for the test 
overall and for the therapy pathways? 
VIII  
28. What assumptions has the model made to accommodate the anticipated 
distribution of therapy options in the target population and links to therapy 
options?  
VIII  
29. Has an electronic copy of the model been provided for each of the target patient 
groups? 
VIII  
30. Has the developer or vendor provided a protocol to detail how the claims for the 
NGS test are to be evaluated for each of the target population groups, together 
with reporting requirements? 
IX  
31. Is the protocol as presented acceptable? IX  
32. Has the developer or vendor agreed to a regular review of test platform 
enhancements and processes to support claims? 
X  
33. Comparator tests: Has the submission identified the potential comparator NGS 
tests? 
Appendix A  
34. Comparator tests: Has the submission summarized the proposed target 
populations for the comparator tests?  
Appendices 
B and C 
 
35. Comparator tests: Has the submission detailed how the comparator tests are to 
be implemented for the proposed target populations?  
Appendix D  
36. Comparator tests: Has the submission detailed the evidence for analytical and 
clinical validity for the comparator tests? 
Appendix D  
37. Comparator tests: Has the submission detailed the evidence base and claims for 
the comparator tests from randomized clinical trials and observational studies? 
Appendix D  
38. Comparator Tests: Has the submission detailed the modeled claims for the 
comparator tests? 
Appendix D  
39. Comparator tests: Do the claims made for the comparator tests meet the 
standards for credibility, evaluation and replication? 
Appendix D  
40. Comparator tests: Has the submission reported any direct/indirect comparisons 
between comparator tests, the proposed test and the standard of care in the 
target patient populations? 
Appendix D  
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CONCLUSIONS 
The purpose of this commentary has been to raise a number 
of key questions regarding (i) the evidence base for NGS 
claims; (ii) the standards required to support NGS claims and 
(iii) the standards required for their introduction to clinical 
practice. 
 
The current evidence base is inadequate. There is not only 
limited evidence for the clinical utility of NGS tests but a 
limited appreciation of the steps required to ensure that 
claims made are validated and that risks to patients are 
adequately protected. While there is little doubt that the 
various NGS tests will be classified as medical devices, we 
have no direction from agencies such as the FDA as to their 
role beyond certifying the test meets standards for analytical 
and clinical validity. Unlike the NICE DAP evidence standards 
where modeled claims for costs and outcomes are requested, 
there is no evidence to date that the FDA will attempt further 
to regulate test claims and the choice of mutation linked 
therapies. Even so, concerns with safety and adverse events 
with what are likely off-label use of a range of pharmaceutical 
products may force the FDA to demand stronger evidence for 
clinical utility, to include risk-mitigation and monitoring 
requirements. 
 
In the absence of standards to evaluate and monitor the 
claims from NGS platforms, the proposal here is that 
formulary committees and health systems take the initiative. 
A range of questions that formulary committees might 
reasonably ask are detailed, together with the proposal that 
submissions for NGS tests should not only be target patient 
specific but should be accompanied by an assessment 
protocol.  
 
At the same time, NGS developers and vendors will face an 
uphill struggle to convince health care systems, treating 
physicians and guideline developers to introduce NGS test 
options into clinical practice. While the evidence base (as 
emphasized) is just too limited, this situation will likely be 
compounded by the number of competing tests and the 
need, from both clinical and cost-effectiveness perspectives, 
to report on the validity of test claims for well-defined 
reference target populations and for the mutation-linked 
therapy choices. Whatever claims are made for individual 
NGS tests, to include claims for the superiority of one test 
over another, the claims made must be credible, evaluable 
and replicable. Health system decision makers will expect no 
less.    
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